Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment‐experienced HIV‐1 patients with virological success: DARDAR study (English)
Free access
- New search for: Schneider, L
- New search for: Houssaini, A
- New search for: Lambert, S
- New search for: Peytavin, G
- New search for: Agher, R
- New search for: Chermak, A
- New search for: Flandre, P
- New search for: Calvez, V
- New search for: Marcelin, AG
- New search for: Ghosn, J
- New search for: Katlama, C
- New search for: Schneider, L
- New search for: Houssaini, A
- New search for: Lambert, S
- New search for: Peytavin, G
- New search for: Agher, R
- New search for: Chermak, A
- New search for: Flandre, P
- New search for: Calvez, V
- New search for: Marcelin, AG
- New search for: Ghosn, J
- New search for: Katlama, C
In:
Journal of the International AIDS Society
;
13
;
P29
;
2010
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment‐experienced HIV‐1 patients with virological success: DARDAR study
-
Contributors:Schneider, L ( author ) / Houssaini, A ( author ) / Lambert, S ( author ) / Peytavin, G ( author ) / Agher, R ( author ) / Chermak, A ( author ) / Flandre, P ( author ) / Calvez, V ( author ) / Marcelin, AG ( author ) / Ghosn, J ( author )
-
Published in:Journal of the International AIDS Society ; 13 ; P29
-
Publisher:
- New search for: The International AIDS Society
-
Publication date:2010-11-01
-
Size:2 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 13
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Highly active antiretroviral treatment for the prevention of HIV transmissionGranich, Reuben / Crowley, Siobhan / Vitoria, Marco / Lo, Ying‐Ru / Souteyrand, Yves / Dye, Christopher / Gilks, Charlie / Guerma, Teguest / De Cock, Kevin M / Williams, Brian et al. | 2010
- 2
-
HIV‐related restrictions on entry, residence and stay in the WHO European Region: a surveyLazarus, Jeffrey V / Curth, Nadja / Weait, Matthew / Matic, Srdan et al. | 2010
- 3
-
Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique ‐ a case studyPfeiffer, James / Montoya, Pablo / Baptista, Alberto J / Karagianis, Marina / Pugas, Marilia de Morais / Micek, Mark / Johnson, Wendy / Sherr, Kenneth / Gimbel, Sarah / Baird, Shelagh et al. | 2010
- 4
-
Impact of HIV‐1 viral subtype on disease progression and response to antiretroviral therapyEasterbrook, Philippa J / Smith, Mel / Mullen, Jane / O'Shea, Siobhan / Chrystie, Ian / de Ruiter, Annemiek / Tatt, Iain D / Geretti, Anna Maria / Zuckerman, Mark et al. | 2010
- 5
-
Sexual vulnerability and HIV seroprevalence among the deaf and hearing impaired in CameroonTouko, Adonis / Mboua, Célestin P / Tohmuntain, Peter M / Perrot, Anne B et al. | 2010
- 6
-
Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and preventionJewkes, Rachel / Morrell, Robert et al. | 2010
- 7
-
Are Nepali students at risk of HIV? A cross‐sectional study of condom use at first sexual intercourse among college students in KathmanduAdhikari, Ramesh et al. | 2010
- 8
-
Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross‐sectional study of cost, stigma, and perceptions about ARTFox, Matthew P / Mazimba, Arthur / Seidenberg, Phil / Crooks, Denise / Sikateyo, Bornwell / Rosen, Sydney et al. | 2010
- 9
-
Challenges faced by health workers in providing counselling services to HIV‐positive children in Uganda: a descriptive studyRujumba, Joseph / Mbasaalaki‐Mwaka, Cissy L / Ndeezi, Grace et al. | 2010
- 10
-
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort studyConkling, Martha / Shutes, Erin L / Karita, Etienne / Chomba, Elwyn / Tichacek, Amanda / Sinkala, Moses / Vwalika, Bellington / Iwanowski, Melissa / Allen, Susan A et al. | 2010
- 11
-
High survival and treatment success sustained after two and three years of first‐line ART for children in CambodiaIsaakidis, Petros / Raguenaud, Marie‐Eve / Te, Vantha / Tray, Chhraing S / Akao, Kazumi / Kumar, Varun / Ngin, Sopheak / Nerrienet, Eric / Zachariah, Rony et al. | 2010
- 12
-
Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross‐sectional studyJang, James J / Schwarcz, Aron I / Amaez, Daniel A / Woodward, Mark / Olin, Jeffrey W / Keller, Marla J / Schecter, Alison D et al. | 2010
- 13
-
Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre‐ and post‐exposure prophylaxis against HIV infectionvan Griensven, Frits / Thienkrua, Warunee / Sukwicha, Wichuda / Wimonsate, Wipas / Chaikummao, Supaporn / Varangrat, Anchalee / Mock, Philip A et al. | 2010
- 14
-
Estimating the cost of care giving on caregivers for people living with HIV and AIDS in Botswana: a cross‐sectional studyAma, Njoku O / Seloilwe, Esther S et al. | 2010
- 15
-
Neurocognitive impairment among HIV‐positive individuals in Botswana: a pilot studyLawler, Kathy / Mosepele, Mosepele / Ratcliffe, Sarah / Seloilwe, Esther / Steele, Katherine / Nthobatsang, Rudo / Steenhoff, Andrew et al. | 2010
- 16
-
An HIV epidemic is ready to emerge in the PhilippinesFarr, Anna C / Wilson, David P et al. | 2010
- 17
-
Kidney function of HIV‐infected children in Lagos, Nigeria: using Filler's serum cystatin C‐based formulaEsezobor, Christopher I / Iroha, Edna / Oladipo, Olajumoke / Onifade, Elizabeth / Soriyan, Oyetunji O / Akinsulie, Adebola O / Temiye, Edamisan O / Ezeaka, Chinyere et al. | 2010
- 18
-
Effect of multiple micronutrient supplementation on survival of HIV‐infected children in Uganda: a randomized, controlled trialNdeezi, Grace / Tylleskär, Thorkild / Ndugwa, Christopher M / Tumwine, James K et al. | 2010
- 19
-
From project aid to sustainable HIV services: a case study from ZambiaTorpey, Kwasi / Mwenda, Lona / Thompson, Catherine / Wamuwi, Edgar / van Damme, Wim et al. | 2010
- 20
-
The experiences of people living with HIV/AIDS and of their direct informal caregivers in a resource‐poor settingMajumdar, Basanti / Mazaleni, Nomathemba et al. | 2010
- 21
-
Is there an association between PEPFAR funding and improvement in national health indicators in Africa? A retrospective studyDuber, Herbert C / Coates, Thomas J / Szekeras, Greg / Kaji, Amy H / Lewis, Roger J et al. | 2010
- 22
-
Perceptions of rewards among volunteer caregivers of people living with AIDS working in faith‐based organizations in South Africa: a qualitative studyAkintola, Olagoke et al. | 2010
- 23
-
AIDS‐associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South AfricaChu, Kathryn M / Mahlangeni, Gcina / Swannet, Sarah / Ford, Nathan P / Boulle, Andrew / Van Cutsem, Gilles et al. | 2010
- 24
-
Planning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunitiesKim, Susan C / Becker, Stephen / Dieffenbach, Carl / Hanewall, Blair S / Hankins, Catherine / Lo, Ying‐Ru / Mellors, John W / O'Reilly, Kevin / Paxton, Lynn / Roffenbender, Jason S et al. | 2010
- 25
-
Low cholesterol? Don't brag yet … hypocholesterolemia blunts HAART effectiveness: a longitudinal studyMíguez, María Jose / Lewis, John E / Bryant, Vaughn E / Rosenberg, Rhonda / Burbano, Ximena / Fishman, Joel / Asthana, Deshratn / Duan, Rui / Madhavan, Nair / Malow, Robert M et al. | 2010
- 26
-
Linking sexual and reproductive health and HIV interventions: a systematic reviewKennedy, Caitlin E / Spaulding, Alicen B / Brickley, Deborah Bain / Almers, Lucy / Mirjahangir, Joy / Packel, Laura / Kennedy, Gail E / Mbizvo, Michael / Collins, Lynn / Osborne, Kevin et al. | 2010
- 27
-
Experiences of stigma in healthcare settings among adults living with HIV in the Islamic Republic of IranRahmati‐Najarkolaei, Fatemeh / Niknami, Shamsaddin / Aminshokravi, Farkhondeh / Bazargan, Mohsen / Ahmadi, Fazlollah / Hadjizadeh, Ebrahim / Tavafian, Sedigheh S et al. | 2010
- 28
-
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV‐1: a study in Côte d'IvoireEkouevi, Didier K / Coffie, Patrick A / Chaix, Marie‐Laure / Tonwe‐Gold, Besigin / Amani‐Bosse, Clarisse / Leroy, Valériane / Abrams, Elaine J / Dabis, François et al. | 2010
- 29
-
High rate of loss to clinical follow up among African HIV‐infected patients attending a London clinic: a retrospective analysis of a clinical cohortGerver, Sarah M / Chadborn, Tim R / Ibrahim, Fowzia / Vatsa, Bela / Delpech, Valerie C / Easterbrook, Philippa J et al. | 2010
- 30
-
An acceptability and safety study of the Duet® cervical barrier and gel delivery system in ZimbabweMontgomery, Elizabeth T / Woodsong, Cynthia / Musara, Petina / Cheng, Helen / Chipato, Tsungai / Moench, Thomas R / Spielberg, Freya / van der Straten, Ariane et al. | 2010
- 31
-
Discontinuation of standard first‐line antiretroviral therapy in a cohort of 1434 Malawian childrenBuck, W Chris / Kabue, Mark M / Kazembe, Peter N / Kline, Mark W et al. | 2010
- 32
-
A process evaluation of the scale up of a youth‐friendly health services initiative in northern TanzaniaRenju, Jenny / Andrew, Bahati / Nyalali, Kija / Kishamawe, Coleman / Kato, Charles / Changalucha, John / Obasi, Angela et al. | 2010
- 33
-
Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV‐1‐infected South African womenAzzoni, Livio / Crowther, Nigel J / Firnhaber, Cynthia / Foulkes, Andrea S / Yin, Xiangfan / Glencross, Deborah / Gross, Robert / Kaplan, Mitch D / Papasavvas, Emmanouil / Schulze, Doreen et al. | 2010
- 34
-
Concurrent sexual partnerships do not explain the HIV epidemics in Africa: a systematic review of the evidenceSawers, Larry / Stillwaggon, Eileen et al. | 2010
- 35
-
A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countriesWaning, Brenda / Diedrichsen, Ellen / Moon, Suerie et al. | 2010
- 36
-
Mothers' knowledge and utilization of prevention of mother to child transmission services in northern TanzaniaFalnes, Eli Fjeld / Tylleskär, Thorkild / de Paoli, Marina Manuela / Manongi, Rachel / Engebretsen, Ingunn MS et al. | 2010
- 37
-
Barriers to accessing highly active antiretroviral therapy by HIV‐positive women attending an antenatal clinic in a regional hospital in western UgandaDuff, Putu / Kipp, Walter / Wild, T Cameron / Rubaale, Tom / Okech‐Ojony, Joa et al. | 2010
- 38
-
Factors associated with access to HIV care and treatment in a prevention of mother to child transmission programme in urban ZimbabweMuchedzi, Auxilia / Chandisarewa, Winfreda / Keatinge, Jo / Stranix‐Chibanda, Lynda / Woelk, Godfrey / Mbizvo, Elizabeth / Shetty, Avinash K et al. | 2010
- 39
-
Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwevan der Straten, Ariane / Cheng, Helen / Minnis, Alexandra M et al. | 2010
- 40
-
New diagnostics for tuberculosis: fulfilling patient needs firstLemaire, Jean‐François / Casenghi, Martina et al. | 2010
- 41
-
Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South AfricaWand, Handan / Ramjee, Gita et al. | 2010
- 42
-
Baseline severe anaemia should not preclude use of zidovudine in antiretroviral‐eligible patients in resource‐limited settingsKiragga, Agnes N / Castelnuovo, Barbara / Nakanjako, Damalie / Manabe, Yukari C et al. | 2010
- 43
-
Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low‐HIV prevalence, low‐resource settingGerlach, Jay / Sequeira, Magda / Alvarado, Vivian / Cerpas, Christian / Balmaseda, Angel / Gonzalez, Alcides / de los Santos, Tala / Levin, Carol E / Amador, Juan Jose / Domingo, Gonzalo J et al. | 2010
- 44
-
Associations between depressive symptoms, sexual behaviour and relationship characteristics: a prospective cohort study of young women and men in the Eastern Cape, South AfricaNduna, Mzikazi / Jewkes, Rachel K / Dunkle, Kristin L / Shai, Nwabisa P Jama / Colman, Ian et al. | 2010
- 45
-
Sexual behaviour does not reflect HIV‐1 prevalence differences: a comparison study of Zimbabwe and TanzaniaMapingure, Munyaradzi P / Msuya, Sia / Kurewa, Nyaradzai E / Munjoma, Marshal W / Sam, Noel / Chirenje, Mike Z / Rusakaniko, Simbarashe / Saugstad, Letten F / de Vlas, Sake J / Stray‐Pedersen, Babill et al. | 2010
- 46
-
Increased vulnerability of rural children on antiretroviral therapy attending public health facilities in South Africa: a retrospective cohort studyFatti, Geoffrey / Bock, Peter / Grimwood, Ashraf / Eley, Brian et al. | 2010
- 47
-
The history of AIDS exceptionalismSmith, Julia H / Whiteside, Alan et al. | 2010
- 48
-
Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretroviralsPhelps, Benjamin R / Hathcock, Sarah J / Werdenberg, Jennifer / Schutze, Gordon E et al. | 2010
- 49
-
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South AfricaBrennan, Alana T / Maskew, Mhairi / Sanne, Ian / Fox, Matthew P et al. | 2010
- 50
-
Experiences of women who have lost young children to AIDS in KwaZulu‐Natal, South Africa: a qualitative studyDemmer, Craig et al. | 2010
- 51
-
Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factorsPetoumenos, Kathy / Hui, Eugenie / Kumarasamy, Nagalingeswaran / Kerr, Stephen J / Choi, Jun Yong / Chen, Yi‐Ming A / Merati, Tuti / Zhang, Fujie / Lim, Poh‐Lian / Sungkanuparph, Somnuek et al. | 2010
- 52
-
Attitudes to routine HIV counselling and testing, and knowledge about prevention of mother to child transmission of HIV in eastern Uganda: a cross‐sectional survey among antenatal attendeesByamugisha, Robert / Tumwine, James K / Ndeezi, Grace / Karamagi, Charles AS / Tylleskär, Thorkild et al. | 2010
- I1
-
Workshop report: “Towards a Cure: HIV Reservoirs and Strategies to Control Them”Jefferys, Richard J et al. | 2010
- I1
-
Visioning services for children affected by HIV and AIDS through a family lensRichter, Linda / Beyrer, Chris / Kippax, Susan / Heidari, Shirin et al. | 2010
- K1
-
Why suppression of HIV replication does not always make everything betterLederman, M et al. | 2010
- K2
-
The public health implications of antiretroviral therapy – 2011 and beyondDe Cock, KM et al. | 2010
- K3
-
ART achievements and challenges in AfricaHakim, J et al. | 2010
- O1
-
CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV‐negative and ART‐suppressed HIV‐positive patients: implications for HIV persistence in the gutYukl, S / Sinclair, E / Epling, L / Li, Q / Shergill, A / McQuaid, K / Duan, L / Hare, B / Lampiris, H / Haase, A et al. | 2010
- O1
-
The changing face of HIV resistance; HIV drug resistance north and south — what's next?Schapiro, J et al. | 2010
- O2
-
International perspectives on adherence and resistance to HIV antiretroviral therapyBangsberg, D et al. | 2010
- O2
-
Most HIV DNA in PBMC is present in non‐gut homing, resting memory CD4+ T cells with a ß7‐CD38‐CD127 high phenotypeKoelsch, KK / Xu, Y / Bailey, M / McBride, K / Seddiki, N / Suzuki, K / Murray, J / Cooper, DA / Kelleher, AD / Zaunders, J et al. | 2010
- O3
-
Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the USSax, PE / Meyers, JL / Mugavero, MJ / Davis, KL et al. | 2010
- O3
-
Where are macrophage‐tropic viruses?Schnell, G / Joseph, S / Spudich, S / Price, R / Swanstrom, R et al. | 2010
- O4
-
Long‐term probability of detecting drug‐resistant HIV in patients starting antiretroviral therapy within the first year of HIV infectionLodi, S / Kücherer, C / Kran, AM Bakken / Masquelier, B / Monforte, A d'Arminio / Gill, J / Dunn, D / Pillay, D / Porter, K et al. | 2010
- O4
-
Novel pathways of transcriptional and post‐transcriptional regulation of post‐integrative HIV‐1 latencyMarcello, A / Kula, A / Dieudonne, M / Knezevich, A / Maiuri, P et al. | 2010
- O5
-
HIV‐1 Tat complexes reveal subunit composition of active P‐TEFb and stable association with 7SKsnRNPSobhian, B / Laguette, N / Yatim, A / Nakamura, M / Levy, Y / Kiernan, R / Benkirane, M et al. | 2010
- O5
-
Low‐level residual viremia and risk of virological failureCologni, G / Soavi, L / Leone, S / Valenti, D / Callegaro, A / Gregis, G / Suter, F / Maggiolo, F et al. | 2010
- O6
-
The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compoundsPironti, A / Sönnerborg, A / Zazzi, M / Kaiser, R / Struck, D / Clotet, B / Vandamme, ÀM / Incardona, F / Lengauer, T / Rosen‐Zvi, M et al. | 2010
- O6
-
Homeostatic proliferation of memory T cells and expansion of the HIV‐1 latent reservoirBosque, A / Planelles, V et al. | 2010
- O7
-
Consensus statement of the European guidelines on clinical management of HIV‐1 tropism testingVandekerckhove, LPR / Wensing, AMJ / Kaiser, R / Brun‐Vezinet, F / Clotet, B / De Luca, A / Dressler, S / Garcia, F / Geretti, AM / Klimkait, T et al. | 2010
- O7
-
Myeloid dendritic cells induce HIV‐1 latency in non‐proliferating CD4+ T cellsEvans, VA / Saleh, S / Haddad, EK / Cameron, PU / Sekaly, R‐P / Lewin, SR et al. | 2010
- O8
-
Calibration and accuracy of the geno2pheno co‐receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotypeSwenson, LC / Knapp, D / Harrigan, PR et al. | 2010
- O8
-
Tetherin restricts direct cell‐cell viral transfer and transmission of HIV‐1Kuhl, BD / Sloan, RD / Donahue, DA / Bar‐Magen, T / Liang, C / Wainberg, MA et al. | 2010
- O9
-
The role of the ubiquitin‐proteasome pathway in rhTRIM5α restriction of HIV‐1Danielson, CM / Hope, TJ et al. | 2010
- O9
-
Short‐term variation of HIV tropism readouts in the absence of CCR5 antagonistsBrumme, CJ / Dong, W / Chan, D / Mo, T / Swenson, LC / Woods, C / Demarest, J / Heera, J / Valdez, H / Harrigan, PR et al. | 2010
- O10
-
Impact of baseline HIV‐1 tropism on viral response and CD4 gains in antiretroviral‐naïve patientsSeclén, E / Gonzalez, M / Martín‐Carbonero, L / Gellermann, H / Cairns, V / Distel, M / Kadus, W / Soriano, V / Poveda, E et al. | 2010
- O10
-
LEDGF/p75 is critical but not essential for multiple‐round HIV 1 replicationSchrijvers, RLG / De Rijck, J / Gijsbers, R / Ronen, K / Bushman, FD / Debyser, Z et al. | 2010
- O11
-
Influence of amount and percentage of CXCR4‐using virus in predicting week 48 responses to maraviroc in treatment‐naïve patientsValdez, H / Chapman, D / Biswai, P / Lewis, M / Craig, C / Heera, J / Ellery, S / Swenson, LC / Harrigan, PR et al. | 2010
- O11
-
Changes in CD4+ cells’ miRNA expression following exposure to HIV‐1Bignami, F / Pilotti, E / Bertoncelli, L / Ronzi, P / Gulli, M / Marmiroli, N / Magnani, G / Pinti, M / Mussini, C / Lopalco, L et al. | 2010
- O12
-
Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV‐1‐infected patients with undetectable viremiaGarrido, C / Rallón, N / Zahonero, N / de la O López, M / Soriano, V / de Mendoza, C / Benito, JM et al. | 2010
- O12
-
Treatment as prevention within the framework of current guidelinesMontaner, J et al. | 2010
- O13
-
Treatment‐as‐prevention: stopping the epidemic of HIVWilliams, B et al. | 2010
- O13
-
Effect of 24 weeks of intensification with a CCR5‐antagonist on the decay of the HIV‐1 latent reservoirDíaz, L / Gutiérrez, C / Page, C / Lorente, R / Hernández‐Novoa, B / Vallejo, A / Domínguez, E / Abad, M / Madrid, N / Moreno, A et al. | 2010
- O14
-
Epigenetic drug Gar1041 in combination with antiretroviral therapy transiently reduces the proviral DNA reservoir in SIVmac251‐infected macaquesLewis, MG / Norelli, S / Chomont, N / De Fonseca, S / Sgarbanti, M / Collins, M / Chirullo, B / Yalley‐Ogunro, J / Greenhouse, J / Palamara, AT et al. | 2010
- O14
-
Test and treat — community perspectivesSpire, B et al. | 2010
- O15
-
HIV treatment as prevention — human rights issuesAmon, J et al. | 2010
- O15
-
Purging the HIV‐1 reservoir through the disruption of the PD‐1 pathwayDaFonseca, S / Chomont, N / El Far, M / Boulassel, R / Routy, J / Sékaly, R et al. | 2010
- O16
-
Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV‐positive patients on HAARTMexas, A / Graf, E / Agosto, L / Yu, JJ / Pace, M / Liszewski, M / Migueles, S / Connors, M / O’Doherty, U et al. | 2010
- O16
-
A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe studySönnerborg, A / Mocroft, A / Lundgren, JD / Raben, D / Gatell, J / Vassilenko, A / Hadziosmanovic, V / Bergovac, J / Sørensen, H / Cusini, M et al. | 2010
- O17
-
The state of PI monotherapy and NRTI‐sparing therapyArribas, JR et al. | 2010
- O18
-
Ritonavir‐boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta‐analysisBierman, WFW / Humphreys, EH / van Agtmael, MA / Boucher, CA / Rutherford, GW et al. | 2010
- O19
-
Low‐level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trialClumeck, N / Arribas, JR / Pulick, P / Fätkenheuer, G / Hill, A / Van Delft, Y / Moecklinghoff, C et al. | 2010
- O20
-
Virological findings from the SARA trial: boosted PI monotherapy as maintenance second‐line ART in AfricaPillay, D / Goodall, R / Gilks, CF / Yirrell, D / Gibb, D / Spyer, M / Kaleebu, P / Munderi, P / Kityo, C / McCormick, A et al. | 2010
- O21
-
Virological outcomes in ARV‐naïve patients switching or not from a first successful boosted PI‐regimen to efavirenz, nevirapine or abacavir regimensBommenel, T / Meynard, JL / Launay, O / Simon, A / Mahamat, A / Martinez, V / Gilquin, J / Katlama, C / Lascaux, AS / Pradier, C et al. | 2010
- O22
-
The clinical development of NRTIs — cautionary talesCooper, D et al. | 2010
- O23
-
Major issues and their solutions in the management of HIV and TB — from the laboratory to the patient and populationSchechter, M et al. | 2010
- O24
-
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin‐based antitubercular treatment in HIV‐infected childrenZhang, C / Denti, P / Simonsson, USH / Maartens, G / Karlsson, MO / McIlleron, H et al. | 2010
- O25
-
Growing old with HIV — dealing with co‐morbiditiesPowderly, W et al. | 2010
- O26
-
HIV therapy in an ageing population — the challenge of polypharmacyBack, DJ et al. | 2010
- O27
-
Impact on life expectancy of late diagnosis and treatment of HIV‐1 infected individuals: UK CHICMay, MT / Gompels, M / Sabin, CA et al. | 2010
- O28
-
Mitochondrial ageing and antiretroviral therapy exposurePayne, BAI / Hateley, CA / Samuels, DC / Wilson, IJ / Santibanez‐Koref, M / Price, DA / Chinnery, PF et al. | 2010
- O29
-
Hepatitis C new drugsWedemeyer, H et al. | 2010
- O30
-
Host genetics of HCV disease — IL28BFellay, J et al. | 2010
- O31
-
Hepatitis C — feedback from the Consensus Conference on the Management of Acute Hepatitis C (AHC) in Paris, May 2010Vogel, M et al. | 2010
- O32
-
Efficacy and safety of peginterferon alfa‐2a + RBV in cHCV/HIV‐ vs cHCV‐infected patients: interim analysis of a multicenter German cohortBaumgarten, A / Lutz, T / Kreckel, P / Wellmann, E / Alshuth, U / Mauss, S / Rockstroh, J et al. | 2010
- O33
-
The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteersAshby, J / Garvey, LJ / Erlwein, OW / Lamba, H / Weston, R / Legg, K / McClure, MO / Dickinson, L / D'Avolio, A / Back, DJ et al. | 2010
- O34
-
How early to start: what do observational data suggest?Sterne, J et al. | 2010
- O35
-
HIV/HAART and the brain — what's going on?Portegies, P et al. | 2010
- O36
-
Adolescents with perinatally acquired HIV — coming your wayFoster, C et al. | 2010
- O37
-
Early mortality following ART initiation in HIV‐infected adults and children in Uganda and ZimbabweWalker, AS / Mugyenyi, P / Munderi, P / Hakim, J / Kekitiinwa, AA / Katabira, E / Gilks, CF / Kityo, C / Nahirya‐Ntege, P / Nathoo, K et al. | 2010
- O38
-
Highlights of the 12th International Workshop on Adverse Drug Reactions and Co‐Morbidities in HIV, London, November 2010Schambelan, M et al. | 2010
- O39
-
Fatal and non‐fatal AIDS and non‐AIDS events in HIV‐1 infected patients with high CD4 countsReekie, J / Gatell, J / Yust, I / Bakowska, E / Rachmanova, A / Losso, M / Krasnov, M / Francioli, P / Kowalska, J / Mocroft, A et al. | 2010
- O40
-
Cardiovascular risk assessment in persons with HIV in the developing world: comparing three risk equations in a cohort of HIV‐infected ThaisEdwards‐Jackson, N / Kerr, SJ / Tieu, HV / Ananworanich, J / Hammer, SM / Ruxrungtham, K / Phanuphak, P / Avihingsanon, A et al. | 2010
- O41
-
What affects the bone in our HIV‐positive patients?Fux, CA et al. | 2010
- O42
-
Vitamin D and HIV: shine a lightCurrier, J et al. | 2010
- O43
-
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA studyViard, JP / Souberbielle, JC / Kirk, O / Knysz, B / Losso, M / Gatell, J / Pedersen, C / Bogner, JR / Mocroft, A / Lundgren, JD et al. | 2010
- O44
-
Maraviroc intensification for HIV‐1‐positive immunological non‐responders (INRs) despite virological suppression during HAARTRusconi, S / Vitiello, P / Adorni, F / Colella, E / Focà, E / Capetti, AF / Meraviglia, P / Abeli, C / Bonora, S / D'Annunzio, M et al. | 2010
- O45
-
Maraviroc (MVC) increases CD4+ and CD8+ cells: long‐term data from the MVC clinical development programLazzarin, A / Sierra‐Madero, JG / Battegay, M / Mukwaya, G / Burnside, R / Chapman, D / McCracken, J / Portsmouth, S / Valluri, S / Valdez, H et al. | 2010
- O46
-
HIV entry blocked by maraviroc can cause an overestimation of viral loadSloan, RD / Kuhl, BD / Kramer, VG / Donahue, DA / Bar‐Magen, T / Tressler, R / Wainberg, MA et al. | 2010
- O47
-
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment‐naïve patientsStellbrink, HJ / Rugina, S / Zagler, C / Esser, S / Castagna, A / Gazzard, B / Hill, A / van Delft, Y / Marks, S et al. | 2010
- O48
-
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patientsCohen, C / Molina, JM / Cahn, P / Clotet, B / Fourie, J / Grinsztejn, B / Hao, W / Johnson, M / Supparatpinyo, K / Crauwels, HM et al. | 2010
- O49
-
Lersivirine: a new NNRTI active across HIV‐1 subtypes with a unique resistance profileMori, J / Westby, M / Tawadrous, M / van der Ryst, E / Charles, C et al. | 2010
- O50
-
Once‐daily S/GSK1349572 combination therapy in antiretroviral‐naïve adults: rapid and potent 24‐week antiviral responses in SPRING‐1 (ING112276)Rockstroh, J / Felizarta, F / Maggiolo, F / Pulido, F / Stellbrink, HJ / Tsybakova, O / Yeni, P / Almond, S / Brothers, C / Song, I et al. | 2010
- O51
-
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)Eron, J / Livrozet, JM / Morlat, P / Lazzarin, A / Katlama, C / Hawkins, T / Fujiwara, T / Cuffe, R / Vavro, C / Santiago, J et al. | 2010
- P1
-
Health‐related quality of life and fatigue in HIV‐1 infected patients diagnosed during primary versus chronic infectionSteingrover, R / Nievaard, MAF / Lange, JMA / Nieuwkerk, PT / Prins, JM et al. | 2010
- P2
-
The management of acute retroviral syndromeHristea, A / Petre, R / Gliga, S / Olaru, I / Ion, M / Moroti, R / Popescu, C / Mihailescu, R / Radulescu, M / Arama, V et al. | 2010
- P3
-
ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adultsOrkin, C / DeJesus, E / Khanlou, H / Stoehr, A / Supparatpinyo, K / Van de Casteele, T / Lathouwers, E / Spinosa‐Guzman, S et al. | 2010
- P4
-
Nevirapine (NVP) vs ritonavir‐boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first‐line therapy: NEWART 48‐week dataDeJesus, E / Mills, A / Bhatti, L / Conner, C / Storfer, S et al. | 2010
- P5
-
Efficacy and safety of an NRTI‐sparing regimen in antiretroviral‐naïve HIV‐infected patients: once‐daily maraviroc plus lopinavir/ritonavirNozza, S / Galli, L / Di Pietro, M / Mazzotta, F / Canducci, F / Pogliaghi, M / Chiappetta, S / Galli, A / Rusconi, V / Salpietro, S et al. | 2010
- P6
-
5‐year safety and efficacy of the once‐daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)Lazzarin, A / Johnson, M / Ribera, E / Weitner, L / Chen, SS / Warren, DR et al. | 2010
- P7
-
SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patientsKumar, P / DeJesus, E / Huhn, G / Sloan, L / Garcia, F / Small, C / Edelstein, H / Felizarta, F / Hao, R / Ha, B et al. | 2010
- P8
-
HRQoL improves in treatment‐naïve HIV‐1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)Baran, RW / Dietz, B / Fredrick, LM / Tian, M / Podsadecki, T et al. | 2010
- P9
-
Outcomes in antiretroviral‐naive HIV‐infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drugBillaud, E / Lacombe, JM / Abgrall, A / Ghosn, J / Launay, O / Livrozet, JM / Meynard, JL / Pavie, J / Costagliola, D et al. | 2010
- P10
-
Comparing the effectiveness of efavirenz and nevirapine for first‐line antiretroviral treatment amongst an adult treatment cohort from South AfricaBock, P / Fatti, G / Grimwood, A et al. | 2010
- P11
-
Comparative efficacy and safety of regimens including ritonavir‐boosted lopinavir or nevirapine in antiretroviral‐naïve HIV‐1‐infected individualsPereira, A / Lopes da Cruz, JP / Carvalho, C / Gonçalves, C / Antunes, F et al. | 2010
- P12
-
Efficacy and safety of TDF/FTC‐containing, first‐line HAART in clinical practice: 3‐year data from the German outpatient cohortvan Lunzen, J / Fätkenheuer, G / Lutz, T / Klauke, S / Mauss, S / Knechten, H / Braun, P / Gallo, L / Goldbach, J et al. | 2010
- P13
-
Reasons for treatment discontinuation in the first year after beginning antiretroviral therapy in a cohort of Portuguese HIV‐infected patientsCaldas, C / Andrade, P / Azevedo, C / Piñeiro, C / Serrão, R / Soares, J / Marques, R / Sarmento, A et al. | 2010
- P14
-
Insights into antiretroviral treatment changes in previously naïve patients: results of a Portuguese cohortSilva, C / Bento, D / Rijo, J / Alfaiate, D / Aldir, I / Araújo, C / Farinha, H / Mansinho, K et al. | 2010
- P15
-
Factors associated with treatment modification during the first year of contemporary HAARTMartin, N / Perez‐Valero, I / San Jose Valiente, B / Mora, M / Bernardino‐Serna, JI / Gonzalez, J / Gaya, F / Zamora, FX / Pena, JM / Arribas, JR et al. | 2010
- P16
-
Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDSPlettenberg, A / Brockmeyer, NH / Haastert, B / Dupke, S / Schewe, CK / Rausch, M / Hower, M / Arendt, G / Jansen, K / KompNet, HIV et al. | 2010
- P17
-
Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir‐containing regimen with low CD4 countsMerlini, E / Sinigaglia, E / Carpani, G / Bini, T / d'Arminio Monforte, A / Marchetti, GC et al. | 2010
- P18
-
Immunological response among patients with undetectable viral load followed for 5 yearsPiñeiro, C / Santos, AS / Cardoso, S / Nuak, J / Lucas, R / Ferreira, A / Xerinda, S / Tavares, M / Marques, R / Sarmento, A et al. | 2010
- P19
-
Epidemiological features, therapeutic strategies and long‐term immunological outcomes in virologically suppressed HIV+ very late presentersMartinelli, L / Francisci, D / Sgrelli, A / Baldelli, F et al. | 2010
- P20
-
Sex matters: retrospective data collection on the date of commencement of ART for HIV‐positive women and men in the German KompNet cohort (1991‐2009)Krznaric, I / Wienbreyer, A / Zoufaly, A / Kreckel, P / Esser, S / Harrer, T / Jansen, K / Michalik, C / Hertling, S et al. | 2010
- P21
-
Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatmentPerez‐Molina, JA / Mora‐Rillo, M / Suarez‐Lozano, I / Casado, JL / Teira, R / Rivas, P / Pedrol, E / Hernando, A / Domingo, P / Barquilla, E et al. | 2010
- P22
-
Eligibility for the initiation of HIV treatment in the context of the updated EACS guidelines: results of a clinical auditAichelburg, MC / Schlag, M / Rieger, A et al. | 2010
- P23
-
Cross‐sectional study of HIV living people cohort to specify indications to antiretroviral treatment in naïve patientsPronin, AJ / Kaminskiy, GD et al. | 2010
- P24
-
Changing antiretrovirals whilst viral load <50 copies/ml and relationship with CD4 count changesMocroft, A et al. | 2010
- P25
-
Influence of demographic and disease parameters on virological response to once‐ vs twice‐daily darunavir/ritonavir (DRV/r) at week 48 in ODINSension, M / Arns Da Cunha, C / Domingo, P / Supparatpinyo, K / Van De Casteele, T / De Doncker, P / Tomaka, F et al. | 2010
- P26
-
Health‐related quality of life (HRQoL) assessment with once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trialSpinosa‐Guzman, S / Van de Casteele, T / De La Rosa, G / De Doncker, P et al. | 2010
- P27
-
Darunavir in experienced patientsSterrantino, G / Borchi, B / Trotta, M / Bartolozzi, D / Leoncini, F et al. | 2010
- P28
-
Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment‐experienced patients: 48‐week data from a German outpatient cohortvan Lunzen, J / Gorriahn, D / Wünsche, T / Dupke, S / Gute, P / Schewe, CK / Ranneberg, B et al. | 2010
- P29
-
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment‐experienced HIV‐1 patients with virological success: DARDAR studySchneider, L / Houssaini, A / Lambert, S / Peytavin, G / Agher, R / Chermak, A / Flandre, P / Calvez, V / Marcelin, AG / Ghosn, J et al. | 2010
- P30
-
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral‐experienced subjects infected with different subtypes of HIV‐1Maroldo, L / Fredrick, LM / Robinson‐Morgan, K / Trinh, R / Podsadecki, TJ et al. | 2010
- P31
-
Long‐term efficacy and safety of atazanavir/ritonavir treatment in a real‐life cohort of treatment‐experienced HIV patientsJansen, K / Sönnerborg, A / Pugliese, P / Biguenet, S / Eychenne, JL / Brockmeyer, NH / Michalik, C / Dupke, S / Jaeger, H / Plettenberg, A et al. | 2010
- P32
-
Integrase inhibitor‐based treatment in clinical practiceCenderello, G / Piscopo, R / Feasi, M / Penco, G / Bobbio, N / Cassola, G et al. | 2010
- P33
-
Switching to a ‘nuke‐sparing’ raltegravir/atazanavir combination: an individualised approachGrant, A / Kamuntu, Y / Read, P / Kulasegaram, R et al. | 2010
- P34
-
Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple‐experienced HIV1‐ and HIV2‐infected patientsDoroana, M / Piñeiro, C / Maltez, F / Fonseca, P / Oliveira, J / Mansinho, K / Horta, A / Teófilo, E / Aguas, M / Germano, I et al. | 2010
- P35
-
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practiceLlibre, JM / Martínez, E / Barreiro, P / Escrig, R / Ribera, E / Cervantes, M / Imaz, A / Gutierrez, F / Knobel, H / Ornelas, A et al. | 2010
- P36
-
Use of once‐daily raltegravir‐based HAART in HIV‐infected injection drug usersTossonian, HK / Raffa, JD / Alenezi, O / Anderson, K / Jassemi, S / Wight, K / DeVlaming, S / Conway, B et al. | 2010
- P37
-
Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997‐2008Bruyand, M / Geffard, S / Lawson‐Ayayi, S / Dauchy, F / Miremont‐Salamé, G / Greib, C / Farbos, S / Morlat, P / Dabis, F et al. | 2010
- P38
-
Long‐term follow‐up of HIV‐infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experienceLandonio, S / Meraviglia, P / Capetti, AF / Di Biagio, A / Lo Caputo, S / Sterrantino, G / Ammassari, A / Menzaghi, B / Franzetti, M / De Socio, G et al. | 2010
- P39
-
Immunologic impact of maraviroc in clinical practice of a university hospitalPaniagua, S Plata / Lopez, N Trovato / Romera, I Castillo / Larisgoitia, A Ais / Cano, J Bellon / Saez, M Sanjurjo et al. | 2010
- P40
-
Short‐course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)Ghosn, J / Delaugerre, C / Pinta, A / Pierre, N / Etienne, D / Raffi, F / Morand‐Joubert, L et al. | 2010
- P41
-
Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r‐experienced HIV‐1 infected patients with suppressed HIV‐1 replication: the RADAR studyGhosn, J / Chermak, A / Houssaini, A / Peytavin, G / Lambert‐Niclot, S / Eychenne, N / Slama, L / Brunet, A / Duvivier, C / Simon, A et al. | 2010
- P42
-
Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 studyCooper, V / Horne, R / Ewan, J et al. | 2010
- P43
-
Long‐term outcomes of switching to fixed‐dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3‐year results of the BICOMBO studyMartínez, E / Arranz, JA / Podzamczer, D / Lonca, M / Sanz, J / Barragán, P / Knobel, H / Ribera, E / Gutierrez, F / Valero, S et al. | 2010
- P44
-
Tolerance and durability of abacavir/lamivudine (ABC/3TC)‐containing regimens: results from a large prospective French cohortCuzin, L / Allavena, C / Levy‐Bachelot, L / Valantin, MA / Mellliez, H / Pugliese, P / Poizot‐Martin, I / Duvivier, C / Finkielsztejn, L / Abel, S et al. | 2010
- P45
-
48‐week efficacy and safety of transitioning virologically stable HIV‐1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)Arastéh, K / Ward, A / Plettenberg, A / Livrozet, JM / Cordes, C / Winston, A / Wang, E / Quinson, A et al. | 2010
- P46
-
Lopinavir to atazanavir or darunavir switch in HIV‐1‐infected patients with dyslipidemia: an observational studyLe Moal, G / Beraud, G / Prazuck, T / Hocqueloux, L / Dupuis, A / Venisse, N et al. | 2010
- P47
-
Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcomeBaudry, T / Boibieux, A / Gagnieu, MC / Cotte, L / Livrozet, JM / Miahles, P / Makhloufi, D / Chidiac, C / Peyramond, D / Ferry, T et al. | 2010
- P48
-
Analysis of determinants of long‐term efficacy of unboosted atazanavir‐based regimens in the clinical settingBonora, S / Calcagno, A / Viganò, O / Bigliano, P / Rusconi, S / Trentini, L / Tettoni, MC / Orofino, G / Salassa, B / Bramato, C et al. | 2010
- P49
-
Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment‐experienced patients (pts) with HIV RNA <50 copies/mLCasado, JL / Domingo, P / Rubio, R / Antela, A / Lopez‐Ruz, MA / Castro, A / Portilla, J / Ribera, E / Podzamczer, D / Oteo, JA et al. | 2010
- P50
-
Lopinavir/ritonavir monotherapy in clinical practiceCaso, A / Valencia, E / Moreno, V / Cervero, M / Sanz, J / Torres Perea, R et al. | 2010
- P51
-
Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategyTyrer, M / Swaden, L / Marshall, NJ / Johnson, M et al. | 2010
- P52
-
Changes in cerebral function parameters in HIV‐1 infected subjects undergoing a treatment simplification to darunavir/ritonavirGarvey, LJ / Higgs, C / Mohammed, P / Nelson, M / Winston, A et al. | 2010
- P53
-
Epidemiological description of the demographic and HIV disease characteristics of HIV patients who are in care but not on treatment in SpainDomingo, P / Arazo, P / Casado, JL / Castaño, MA / Ferrer, E / Goenaga, MA / Granados, R / Pulido, F / Rodriguez, J / Rubio, R et al. | 2010
- P54
-
Treatment of HIV‐2 infection: a retrospective study from a Portuguese centerMarques, N / Seixas, D / Crespo, P / Malcata, L / Vaz, J / Mota, V / Morais, C / Oliveira, J / Duque, V / Saraiva da Cunha, J et al. | 2010
- P55
-
The prognosis of patients with dissociated virological and immunological responses to HAARTJevtovic, DJ / Salemovic, DR / Ranin, JT et al. | 2010
- P56
-
Prediction of virological failure in HIV‐infected individuals treated with cART in SurinameBleijenberg, MP / Bierman, WFW / Jaglall, C / Heymans, MW / ten Doesschate, MC / Nieuwkerk, PT / Smits, PH / van Eer, M / Vreden, S et al. | 2010
- P57
-
British HIV and ageing study. HIV and ageing: older people with HIV, who are they?Allan, S / Daly, RA / Yoganathan, Y / Barrett, S / Joseph, A / Tariq, A / Saing, CW / Williams, C / Lane, C / Sikorska, J et al. | 2010
- P58
-
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once‐daily vs. twice daily lopinavir/ritonavir (LPV/r) regimensQaqish, R / van Wyk, J / King, MS et al. | 2010
- P60
-
Long‐term efficacy and safety of low‐dose ritonavir‐boosted atazanavir (ATV/r) 200/100 mg in HIV‐infected Thai patientsAvihingsanon, A / Apornpong, T / Kerr, SJ / Ananworanich, J / Ruxrungtham, K et al. | 2010
- P61
-
Immune impairment and adaptive response in relation to antiretroviral therapy of HIV‐infectionKaminskiy, GD / Pronin, AJ et al. | 2010
- P62
-
Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovirFrancisci, D / Falcinelli, E / Belfiori, B / Petito, E / Mezzasoma, M / Baldelli, F / Gresele, P et al. | 2010
- P63
-
Platelet activity in HIV‐infected patients on abacavir‐containing antiretroviral therapyPalacios, R / González‐Correa, JA / Ruiz, J / Nuño, E / Márquez, M / de la Cruz, JP / Santos, J et al. | 2010
- P64
-
Cardiovascular risk in patients visiting the Hadassah AIDS Center, JerusalemSchulman, S / Rotshild, V / Pops, K Olshtein / Korem, M / Israel, S / Hauzi, M / Maayan, S et al. | 2010
- P65
-
Incidence of ischemic cardiovascular events in the maraviroc clinical development programPortsmouth, S / Burnside, R / Lazzarin, A / Johnson, M / Valdez, H et al. | 2010
- P66
-
Low serum phosphate levels are related to increased cardiovascular risk in HIV‐1 infected patientsGrima, P / Guido, M / Chiavaroli, R / Tundo, P / Zizza, A et al. | 2010
- P67
-
Prevalence of cardiovascular risk factors in Spanish HIV‐1‐infected male inmatesGolf, JP / Sala, L / Aramburo, J / Sardà, P / Perez‐Alvarez, N / Llibre, JM et al. | 2010
- P68
-
Nitric oxide protects against HIV gp120 endothelial injuryFiorucci, S / Mencarelli, A / Francisci, D / Distrutti, E / Renga, B / Baldelli, F et al. | 2010
- P69
-
Higher red blood cell distribution width is associated with a worse virologic and clinical situation in HIV‐infected patientsPuerta, S / Gallego, M / Palacios, R / Ruiz, J / Nuño, E / Márquez, M / Santos, J et al. | 2010
- P70
-
Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV‐infected patientsVadini, F / Sozio, F / Mazzotta, E / Agostinone, C / Ursini, T / Agostinone, A / Placido, G / Manzoli, LM / Parruti, G et al. | 2010
- P71
-
Lipodystrophy and metabolic syndrome in Romanian HIV‐infected adultsArbune, M et al. | 2010
- P72
-
Mesenteric fat thickness in a group of HIV patients on HAARTLee, SS / Liu, E / To, KW et al. | 2010
- P73
-
Hypertriglyceridemic waist identifies HIV+ men and women at increased cardiometabolic riskGuaraldi, G / Zona, S / Orlando, G / Carli, F / Stentarelli, C / Despres, J / Ross, R et al. | 2010
- P74
-
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavirOverton, T / Aberg, JA / Gupta, S / Ryan, R / Baugh, B / De La Rosa, G et al. | 2010
- P75
-
Adiponectin and leptin levels in HIV‐infected patients with lipodystrophy in Southern IndiaJacob, S Mini / Phoebe, K Annie / Hemalatha, R / Sivakumar, MR / Ravindran, MP / Natarajan, MV et al. | 2010
- P76
-
Nutritional status in HIV‐infected patients using Changi's mini nutritional assessmentCervero, M / Alcázar, V / Sanz, R / García‐La Calle, C / Agud, JL et al. | 2010
- P77
-
Dietician‐based approach to lipodystrophic syndrome: role of bioelectrical impedance analysis at week 12Orofino, G / Guastavigna, M / Martinoglio, P / Penoncelli, D / Demarie, D / Tettoni, M / Desiderato, P / Di Frenna, R / Zignin, C et al. | 2010
- P78
-
Altered phosphate metabolism in HIV‐1‐infected patients: another feature of metabolic syndrome?Grima, P / Zizza, A / Guido, M / Calabrese, P / Chiavaroli, R / Sodo, MR / Tana, M / Tundo, P et al. | 2010
- P79
-
Switching to nevirapine (NVP) significantly increases high‐density lipoprotein cholesterol (HDL‐C) in treatment‐experienced patients (NEVICOR study)Rodriguez, JM / Delgado, M / Viciana, P / Lopez‐Ruz, MA / Leal, M / Alcacer, F / Deig, E / Antela, A / Pedrol, E / Moreno, S et al. | 2010
- P80
-
Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24‐week, randomized studyMoyle, G / Orkin, C / Fisher, M / Anderson, J / Dhar, J / Wang, MH / Ewan, J et al. | 2010
- P81
-
CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine‐based regimens for a median of 9 yearsPodzamczer, D / Tiraboschi, JM / Mallolas, J / Cárdenes, MA / Casas, E / Castro, A / Echevarria, S / Leal, M / Bernanldo de Quirós, JC Lopez / Moreno, S et al. | 2010
- P82
-
Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDARyom, L / Mocroft, A / Reiss, P / Ledergerber, B / De Wit, S / Duiculescu, D / Monforte, AD / Murphy, M / Lundgren, JD / Kirk, O et al. | 2010
- P83
-
Kidney tubular function and serum phosphate levels in HIV‐1‐infected patients treated with tenofovir: preliminary resultsGrima, P / Zizza, A / Calabrese, P / Chiavaroli, R / Faraone, A / Tana, M / Sodo, MR / Tundo, P / Guido, M et al. | 2010
- P84
-
Smoking, female gender and PI use are associated with decreasing renal function in TDF‐containing HAARTUglietti, A / Gervasoni, C / Gabrielli, E / Di Giambenedetto, S / Cauda, R / Esposito, R / Grima, P / Di Perri, G / Maserati, R / Galli, M et al. | 2010
- P85
-
A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first‐line HAART (the INCA trial)Izzo, I / Albini, L / Calabresi, A / Motta, D / Bellagamba, R / Fezza, R / Narciso, P / Sighinolfi, L / Maggi, P / Focà, E et al. | 2010
- P86
-
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)‐containing once‐daily highly active antiretroviral therapy (HAART)Cassetti, I / Etzel, A / Madruga, JV / Suleiman, JM / Zhou, Y / Rhee, M / Warren, DR et al. | 2010
- P87
-
Intracellular tenofovir‐diphosphate accumulation in an HIV‐infected patient with Fanconi syndrome and osteomalaciaHaverkort, ME / van der Spek, BW / Lips, PT / Slieker, WAT / Bronsveld, W et al. | 2010
- P88
-
The association between metabolic syndrome and the occurrence of nephrolithiasis in HIV‐infected patientsDumitru, IM / Rugina, S / Sotila, G / Dumitru, E / Rugina, CN et al. | 2010
- P89
-
Prevalence of chronic renal failure stage 3 or more in HIV‐infected patients in Antwerp: an observational studyColson, AW / Florence, E / Augustijn, H / Verpooten, GA / Lynen, L / Gheuens, E et al. | 2010
- P90
-
Hepatotoxicity in patients co‐infected with HIV and tuberculosis while receiving NNRTI‐based antiretroviral regimen and rifampicinMankhatitham, W / Lueangniyomkul, A / Manosuthi, W et al. | 2010
- P91
-
Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir‐boosted protease inhibitor in HIV/HCV‐coinfected drug‐naïve patientsMacías, J / Mallolas, J / López‐Cortés, LF / Cartón, JA / Domingo, P / Moreno, S / Iribarren, JA / Neukam, K / Rodrigo, A / Jiménez‐Expósito, MJ et al. | 2010
- P92
-
Liver fibrosis: concordance analysis between APRI and FIB‐4 scores, evolution and predictors in a cohort of HIV patients without HCV and HBV infectionMendeni, M / Focà, E / Gotti, D / Ladisa, N / Quiros‐Roldan, E / Vavassori, A / Castelnuovo, F / Carosi, G / Angarano, G / Torti, C et al. | 2010
- P93
-
Clinical significance of hyperbilirubinemia in the CASTLE studyUy, J / Hu, W / Wirtz, V / Hosey, T / Butcher, D / McGrath, D / Farajallah, A et al. | 2010
- P94
-
A case of nodular regenerative hyperplasia in a patient who had been taking didanosineJackson, C / Fox, R / Priest, M / Clutterbuck, D / Peters, E et al. | 2010
- P95
-
Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4‐cell declinede Jong, E / Haverkort, ME / ter Heine, R / Jansen, RS / Beijnen, JH / van Agtmael, MA et al. | 2010
- P96
-
Lack of association between mitochondrial DNA polymorphisms and didexoxynucleoside‐induced hyperlactataemia in black‐African, HIV‐1‐infected patientsArenas‐Pinto, A / Weller, I / Ekong, R / Grant, A / Karstaedt, A / Telisinghe, L / Bolhaar, M / Charalambous, S / Bradman, N / Ingram, C et al. | 2010
- P97
-
Markers of bone turnover are elevated in patients on antiretrovirals independent of the substance usedPiso, RJ / Rothen, M / Rothen, JP / Stahl, M et al. | 2010
- P98
-
Quantitative ultrasound (QUS) in HIV‐infected patients: a reliable and low‐cost technique for bone health assessmentMarocco, R / Martini, H / Belvisi, V / Tieghi, T / Cesareo, R / Del Borgo, C / Lichtner, M / Mastroianni, CM et al. | 2010
- P99
-
Fracture risk in HIV and the need for guidelines: the Probono‐1 TrialPeters, B / Isohanni, H / Tillet, S / Ibrahim, F / Hampson, G / Williams, FMK / Perry, MEO / Duncan, A / Wierzbicki, A et al. | 2010
- P100
-
Rates of bone fractures in a cohort of HIV‐infected adults in the UKSamarawickrama, A / Malik, R / Fisher, M / Gilleece, Y / Walker‐Bone, K et al. | 2010
- P101
-
Prevalence of vitamin D deficiency: cross‐sectional study of a hospital cohort of HIV‐1 infected outpatientsCervero, M / Alcázar, V / García‐La Calle, C / Sanz, R / Agud, JL et al. | 2010
- P102
-
The serum level of 25‐OH vitamin D and Th1 cytokine pattern in HIV infection versus hepatitis C virus infection and hepatitis B virus infectionIacob, SA / Banica, D / Panaitescu, E / Cojocaru, M / Iacob, D et al. | 2010
- P103
-
Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co‐infected patientsSurah, S / Samarawickrama, A / Campbell, L / Kulasegaram, R / Post, F / Fisher, M / Peters, B / Fox, J et al. | 2010
- P104
-
Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohortCervero, M / García Lacalle, C / Agud, JL / Perea, R Torres / García‐Benaya, E / Jusdado, J / Pons, C Pérez / del Álamo, M et al. | 2010
- P105
-
Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment‐experienced (TE) patients in BrazilFurtado, JJD / Madruga, JV / Bicudo, EL / Eira, M / Lopes, MIB / Netto, EM / de Oliveira, MS / Leite, OHM / Machado, AA / Tupinambas, U et al. | 2010
- P106
-
Behaviour and attitudes in HIV (BEAHIV): a national survey study to examine the level of agreement between physicians and patients in symptom reportingRachlis, A / Gill, J / Harris, M / Macleod, J / Worthington, C / Brunetta, J / Tsang, A / Hew, H / Leith, J / Camacho, F et al. | 2010
- P107
-
Continuing burden of HIV late presenters in the North East of England 2009Premchand, N / Golds, K / Tan, PY / Bittiner, I / Sanker, N / Ong, ELC et al. | 2010
- P108
-
Drug interactions in the elderly HIV‐infected patientCoroiu, C / Tollinchi, F / Hittinger, G / Mokhtari, S / Granet, P / Faucher‐Zaegel, O / Madrid, A / Menard, A / Mattei, JL / Chadapaud, S et al. | 2010
- P109
-
Sexual dysfunction and anxiety in HIV‐1‐infected males in Eastern SicilyCelesia, BM / Coco, C / Bisicchia, F / Pellicanò, G / Mughini, MT / Palermo, F / Nunnari, G / Russo, R et al. | 2010
- P110
-
Raltegravir‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safetyPerry, MEO / Almaani, N / Desai, N / Fox, J / Larbalestier, N / Chilton, D et al. | 2010
- P111
-
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter studyMadeddu, G / Soddu, V / Ricci, E / Quirino, T / Menzaghi, B / Bellacosa, C / Grosso, C / Melzi, S / Valsecchi, L / Franzetti, M et al. | 2010
- P112
-
Efavirenz use and contraceptive methods in HIV‐positive women in a large urban cohortSeaton, RA / Fox, R / MacConnachie, A / Anderson, P / Nandwani, R / Peters, E / Winter, A / Taylor, R et al. | 2010
- P113
-
Assessing the risk of birth defects associated with atazanavir exposure in pregnancyEsker, S / Albano, J / Tilson, H / Uy, J / Arikan, D / Krantz, K / Jiménez‐Expósito, MJ / Seekins, D et al. | 2010
- P114
-
Administration of darunavir tablets in patients with difficulties in swallowing – two case reportsScholten, S / Mauruschat, S / Hindermann, S / Ranneberg, B et al. | 2010
- P115
-
Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?Seden, K / Back, DJ / Khoo, SH et al. | 2010
- P116
-
Adherence, quality of life and number of daily pills in a large cross‐sectional studyGianotti, N / Galli, L / Bocchiola, B / Cahua, T / Panzini, P / Zandonà, D / Salpietro, S / Maillard, M / Danise, A / Pazzi, A et al. | 2010
- P117
-
Changing HIV guidelines: how to communicate treatment startFehr, J / Nicca, D / Langewitz, W / Haerry, D / Battegay, M et al. | 2010
- P118
-
Relating protease inhibitor resistance at time of virological failure with drug exposureVan Luin, M / Bannister, WP / Paredes, R / Phillips, AN / Bruun, J / Van Lunzen, J / Kirk, O / d'Arminio Monforte, A / Cozzi‐Lepri, A / Burger, DM et al. | 2010
- P120
-
Does feedback of medication execution using MEMS caps aid adherence to HAART?: the MEMRI study (MEMS as Realistic Intervention)Davies, S / Asghar, S / Cooper, V / Lange, A / Robertson, C / Vrijens, B / White, DJ et al. | 2010
- P121
-
Antiretroviral regimen complexity as a predictor of adherenceBoyle, C / Wilson, A / Treacy, G / Sheehan, G / Lambert, J / Meegan, C / Mallon, P et al. | 2010
- P122
-
Naïve patients receiving TDF/FTC‐EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pillPerez‐Valero, I / Martin, N / Valiente, B San Jose / Bernardino‐Serna, JI / Mora, M / Gaya, F / Gonzalez, J / Zamora, FX / Pena, JM / Arribas, JR et al. | 2010
- P123
-
High level of adherence to HAART among refugees and internally displaced persons on HAART in western equatorial region of Southern SudanSalami, O / Buzu, A / Nzeme, C et al. | 2010
- P124
-
Identifying causes of loss to follow up in newly diagnosed HIV‐infected patientsFridman, V / Bello, NS / Lasala, MB et al. | 2010
- P125
-
Transmitted drug resistance associated with transmission clusters in newly diagnosed antiretroviral‐naïve patients in Northern GreeceSkoura, L / Metallidis, S / Buckton, AJ / Mbisa, JL / Pilalas, D / Papadimitriou, E / Papoutsi, A / Haidich, AB / Valagouti, D / Tsachouridou, O et al. | 2010
- P126
-
Analysis of transmitted drug resistance, resistance mutations and future antiretroviral efficacy in HIV‐1 subtype F infected‐patients prior to therapyManolescu, LSC / Sultana, CM / Vagu, C / Temereanca, A / Ruta, SM et al. | 2010
- P127
-
Detection of HIV type 1 mutations on the pol region in untreated patients in Northern Vietnam: determination of drug resistance and subtypesRanger‐Rogez, S / Al Jawhari, M / Nguyen, B / Pham Hong, N / Tran Quoc, T / Pascual, J / Doll, J / Harzic, M / Viretto, G / Weinbreck, P et al. | 2010
- P128
-
Population and ultra‐deep sequencing for tropism determination are correlated with Trofile ES: genotypic re‐analysis of the A4001078 maraviroc studyPortsmouth, S / Valluri, S / Daeumer, M / Thiele, B / Valdez, H / Lewis, M / Craig, C / Thielen, A / James, I / Demarest, J et al. | 2010
- P129
-
Clinical application of genotypic co‐receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohortObermeier, MJ / Carganico, A / Dupke, S / Schranz, D / Cordes, C / Freiwald, M / Klausen, G / Köppe, S / Schuler, C / Mayr, C et al. | 2010
- P130
-
Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRVRockstroh, J / Eron, J / Cooper, D / Steigbigel, R / Nguyen, BY / Xu, X / Wan, H / Rodgers, A / Miller, M / Leavitt, R et al. | 2010
- P131
-
Analysis of major and minor IAS‐USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIsPulido, F / Arribas, JR / Hill, A / van Delft, Y / Moecklinghoff, C et al. | 2010
- P132
-
Changing prevalence of darunavir resistance‐associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003‐2009De La Rosa, G / Pattery, T / Picchio, G / Lathouwers, E / Villacian, J / Van der Borght, K et al. | 2010
- P133
-
Darunavir resistance spectrum in darunavir‐naᵢve patients harboring virological failure to antiretroviral therapyMarcelin, AG / Charpentier, C / Wirden, M / Descamps, D / Calvez, V et al. | 2010
- P134
-
Resistance after viral failure on atazanavir‐containing therapy: multinational clinical cohort (BMS AI424‐128 — ‘IMPACT’) final analysisZolopa, A / Towner, W / Lazzarin, A / Fätkenheuer, G / Butcher, D / Uy, J et al. | 2010
- P135
-
High levels of polymorphisms related to raltegravir resistance among raltegravir‐naïve individuals in BrazilPena, N Mantovani / Azevedo, R Gonçalves / Castro, D Funayama / Diaz, R Sobhie / Komninakis, S Vasconcelos et al. | 2010
- P136
-
Prevalence of resistance and HIV‐1 protease mutation patterns after failures with fosamprenavir‐containing regimensMarcelin, AG / Charpentier, C / Ferreira, C / Wirden, M / Lemarchand, C / Descamps, D / Calvez, V et al. | 2010
- P138
-
Is extended resistance to the historical antiretroviral drugs & drug classes still a risk factor for HIV progression?Zaccarelli, M / Lorenzini, P / Marconi, P / Forbici, F / Gori, C / Sette, P / Ceccherini‐Silberstein, F / Narciso, P / Perno, CF / Antinori, A et al. | 2010
- P139
-
Prevalence of HIV drug‐resistance mutations in HIV‐infected Mexican patients heavily experienced to antiretroviral therapyGaytán‐Martínez, JE / Mata‐Marín, JA / Gutierrez‐Escolano, F / Pérez‐Saleme, L / Treviño‐Pérez, S / Vázquez‐Rosales, JG / Matías‐Juan, N / Díaz‐Ramos, RD / Arias‐Flores, R et al. | 2010
- P140
-
HIV drug resistance in children with treatment failure to first‐line regimens in Ho Chi Minh City, VietnamNhung, VTT / Colby, D / Khanh, TH / Viet, TT / Lu, D / Thuy, HT / An, B / Giang, LT et al. | 2010
- P141
-
Molecular epidemiology of antiretroviral resistance in therapy‐experienced HIV‐1 patients in Cuba (2009)Pérez, L / Aleman, J / Correa, C / Pérez, J / Fonseca, C / Aragones, C / Pérez, D / Alvarez, A / Vandamme, AM / Kourí, V et al. | 2010
- P142
-
Development of drug resistance among HIV‐1 F1 sub‐type patients with treatment failureTemereanca, A / Sultana, CM / Manolescu, L / Vagu, C / Grancea, C / Ruta, S et al. | 2010
- P143
-
Pro‐viral DNA and antiretroviral treatment simplificationZucman, D / Rouzioux, C / Avettand‐Fenoel, V et al. | 2010
- P144
-
Haemoglobin and anaemia in the SMART studyMocroft, A / Lifson, AR / Touloumi, G / Neuhaus, J / Fox, Z / Palfreeman, A / Vjecha, M / Hodder, S / De Wit, S / Lundgren, JD et al. | 2010
- P145
-
Genotype testing in HIV‐infected pregnant womenAfonso, C / Zagalo, A / Janeiro, N / Antunes, F et al. | 2010
- P146
-
High prevalence of the UGT1A1*28 variant in HIV‐infected individuals in GreecePanagopoulos, P / Paraskevis, D / Sypsa, V / Detsika, M / Protopapas, K / Sakka, V / Poulakou, G / Papadopoulos, A / Petrikkos, G / Hatzakis, A et al. | 2010
- P147
-
Feasibility of testing antibodies to HIV from filter paper using HIV rapid test kitsGanesan, A / Thatchinamoorthy, G / Saramini, S et al. | 2010
- P148
-
Effect of lipemia and bilirubinemia on HIV‐1 protease and reverse transcriptase genotyping and phenotyping success: a five‐year analysisPattery, T / Van Cauwenberge, A / Van Hove, M / Smits, V / Van Soom, K / Villacian, J et al. | 2010
- P149
-
Development of a single‐tube, low‐cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co‐infected patientsFox, D / O’Connor, R / Mallon, P / McMahon, G et al. | 2010
- P150
-
Lack of utility of phosphate serum monitoring in HIV‐infected patients on a tenofovir‐based antiretroviral regimenWikman, P / Safont, P / Perez‐Elías, MJ / Moreno, A / Dronda, F / Moreno, S / Casado, JL et al. | 2010
- P151
-
CCR5 D32 modifies 15‐year mortality risk associated with well‐established clinical and immunological factors among HIV‐infected patientsParczewski, M / Leszczyszyn‐Pynka, M / Bander, D / Urbañska, A / Kaczmarczyk, M / Ciechanowicz, S / Boron‐Kaczmarska, A et al. | 2010
- P152
-
What drives a normal relation between T‐CD4 and T‐CD8?Badura, R / Antunes, RJG / Janeiro, N / Afonso, C / Antunes, F et al. | 2010
- P153
-
Comparative evaluation of ARV therapy efficiency among patients at the Kiev regional AIDS centerYurchenko, YO / Stepchenkova, T / Karnets, KI / Martinenko, MO et al. | 2010
- P154
-
Feasibility and effectiveness of combination antiretroviral therapy in HIV‐infected infants in Pietermaritzburg, South AfricaVan der Linden, D / Purchase, S / McKerrow, NH et al. | 2010
- P155
-
Promoting presumptive diagnosis of severe HIV disease to increase uptake of antiretroviral therapy in HIV‐infected infantsChiwoko, J / Mhango, E / Phiri, S / Weigel, R et al. | 2010
- P156
-
Audit of outcomes of early initiation of antiretroviral therapy in children admitted to the paediatric wards at Kilifi district hospital, KenyaNabwera, HM / Mwaringa, S / Kimutai, R / Berkley, JA et al. | 2010
- P157
-
Salvage therapy with raltegravir in a 3‐month‐old infantBrolund, AB / Ilchmann, C / Ganschow, R / Degen, O et al. | 2010
- P158
-
High preterm delivery rates associated with initiation of HAART during pregnancyTaylor, GP / Douglas, M / Smith, J et al. | 2010
- P159
-
Minority M184V variants in women exposed to 3TC/FTC‐containing lopinavir‐ritonavir (LPVr) regimens in pregnancySurah, S / Oshea, S / Costelloe, S / Hanlon, M / Mullen, J / Chrystie, I / Taylor, GP / De Ruiter, A et al. | 2010
- P160
-
Antiretroviral strategies for the treatment of pregnant HIV+ women and prevention of perinatal HIV transmission in Dodoma, Tanzania: AMANI StudyLiuzzi, G / Vairo, F / Chaula, Z / Nguhuni, B / Nicastri, E / Bevilacqua, N / Cannas, A / Paglia, MG / Ippolito, G et al. | 2010
- P161
-
Use of antiretroviral therapy during pregnancy among HIV‐infected women attending an urban care centreSsewankambo, F / Nalugwa, C / Sempa, J / Walusimbi, J / Kambugu, A et al. | 2010
- P162
-
A complex of measures effectiveness in reducing mother‐to‐child HIV transmissionMinaeva, SV / Moshkovich, GF et al. | 2010
- P163
-
Amniocentesis is a low‐risk procedure in HIV‐treated pregnant womenSimoes, MM / Marques, CO / Albergaria, F / Guerreiro, C / Pereira, A / Correia, J / Castela, J et al. | 2010
- P164
-
Pregnancy decisions and contraceptive use among HIV‐positive women: a study in a large urban clinic in sub‐Saharan AfricaWalusimbi, J / Birabwa, E / Nabankema, E / AnneMarie, A / Lutalo, I / Nakiwooga, A et al. | 2010
- P165
-
A method to estimate the number of people in a country or region with HIV who are undiagnosed and in need of ARTLodwick, RK / Sabin, CA / Phillips, AN et al. | 2010
- P166
-
BEST: Better Equipped to Start TreatmentBennett, J et al. | 2010
- P167
-
Older HIV‐infected individuals present late and have a higher mortality: a UK clinic cohort studyIwuji, CC / Pao, D / Gilleece, Y / Fisher, M / Churchill, D et al. | 2010
- P168
-
Offering HIV testing in an emergency admission unit in Newcastle upon Tyne, UK — a pilot audit studyEllis, S / Graham, L / Price, DA / Ong, ELC et al. | 2010
- P169
-
A high occurrence of late presenters and missed HIV diagnosis in clinical care in SwedenBrännström, J / Svedhem, V / Yilmaz, A / Blaxhult, A / Wendahl, S / Sönnerborg, A et al. | 2010
- P170
-
Audit of telephone HIV clinics: effective and acceptableWoolley, WFC / Babu, C / Sukthankar, A / McQuillan, O et al. | 2010
- P171
-
Newly diagnosed HIV patients in Lima, Peru: a comparison of individuals diagnosed through an intervention program versus self‐referred individualsHidalgo, JA / Castillo, N / Agurto, C et al. | 2010
- P172
-
Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in AustraliaBloch, M / Hoy, J / Cunningham, N / Roth, N / Andrianopoulos, N / Rayner, C / Carr, A et al. | 2010
- P173
-
Five‐year outcomes of HAART at a non‐governmental treatment center in Lima, PeruCastillo, N / Agurto, C / Benites, C / Hidalgo, JA et al. | 2010
- P174
-
The impact of late presentation: analysis of a cohort of 313 Portuguese patientsAlfaiate, D / Miranda, AC / Rijo, J / Fernandes, D / Borges, F / Farinha, H / Mansinho, K et al. | 2010
- P175
-
T‐CD4+ cell count at the date of the HIV diagnosisDomingues da Silva, AR / Mendez, J / e Castro, R Sarmento et al. | 2010
- P176
-
Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV‐1‐infected Ugandan childrenGitta, PK / Kendall, L / Musiime, V / Adkison, K / Kekitiinwa, AA / Ferrier, A / Opilo, O / Lou, Y / Bwakura‐Dangarembi, MF / Nahirya‐Ntege, P et al. | 2010
- P177
-
Therapeutic drug monitoring (TDM) of atazanavir in pregnancyElse, LJ / Jackson, V / Brennan, M / Breiden, J / Weldridge, C / Coulter‐Smith, S / Back, DJ / Khoo, SH / Lambert, J et al. | 2010
- P178
-
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV‐infected patientsSiccardi, M / D'Avolio, A / Baietto, L / Simiele, M / Bonora, S / Back, DJ / Di Perri, G / Owen, A et al. | 2010
- P179
-
A filter‐based cross‐sectional analysis of an HIV‐positive, HAART‐treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral loadCalcagno, A / Milia, MG / D'Avolio, A / Ndayishimiyae, P / Dusabimana, P / Bonora, S / Cusato, J / Simiele, M / Rostagno, R / Siccardi, M et al. | 2010
- P180
-
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV‐negative volunteersJackson, AGA / Hill, A / Else, LJ / Back, DJ / Morley, R / Puls, R / Amin, J / Lin, E / Boffito, M et al. | 2010
- P181
-
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV‐infected patients from MalawiDickinson, L / Chaponda, M / Carr, D / van Oosterhout, JJ / Kumwenda, J / Lalloo, DG / Pirmohamed, M / Heyderman, R / Khoo, SH et al. | 2010
- P182
-
PK/PD modeling supports the dose‐escalation decision in VIKINGLovern, M / Underwood, M / Nichols, G / Song, I et al. | 2010
- P183
-
Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV‐infected patientsZhang, Y / Owen, A / Egan, D / Sarfo, SF et al. | 2010
- P184
-
Population pharmacokinetic modelling of once‐daily ritonavir‐boosted darunavir in HIV‐infected patientsDickinson, L / Jackson, AGA / Garvey, LJ / Watson, V / Khoo, SH / Winston, A / Boffito, M / Davies, GR / Back, DJ et al. | 2010
- P185
-
Pharmacokinetic (PK) and pharmacodynamic analyses of once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trialSekar, V / De La Rosa, G / Van de Casteele, T / Spinosa‐Guzman, S / Vis, P / Hoetelmans, RMW et al. | 2010
- P186
-
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVECrauwels, HM / van Schaick, E / van Heeswijk, RPG / Vanveggel, S / Boven, K / Vis, P et al. | 2010
- P187
-
Herb‐drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV‐infected patientsMoltó, J / Valle, M / Miranda, C / Cedeño, S / Negredo, E / Barbanoj, MJ / Clotet, B et al. | 2010
- P188
-
Moringa oleifera supplementation by patients on antiretroviral therapyMonera, TG / Maponga, CC et al. | 2010
- P189
-
The use of a darunavir/ritonavir once‐daily regimen in two pregnant womenLambert, JS / Else, LJ / Jackson, V / Dickinson, L / Back, DJ / Brennan, M / Weldridge, C / Coulter‐Smith, S / Gibbons, S / Khoo, SH et al. | 2010
- P190
-
Treatment of chronic invasive fungal sinusitis with voriconazole in an HIV patientHo, A / McGarry, G / Peters, E et al. | 2010
- P191
-
Opportunistic infections (OIs) present in HIV‐seropositive patients: a studyRamaiah, K Ayodhya / Sudha Rani, B / Anand, R / Ramola, S / Satish Babu, P / Ramesh Babu, R et al. | 2010
- P192
-
Immunological diagnosis of CMV infection in HIV‐infected patientsDumitru, IM / Rugina, S / Dumitru, E / Cernat, RC / Diaconu, S / Mitroi, C Maxim et al. | 2010
- P193
-
Epidemiology of HIV‐associated tuberculosis (TB) co‐infection in Krasnoyarsk region, Russian FederationChaychuk, TA / Gankina, NU / Nikonova, OG et al. | 2010
- P194
-
A minority of tuberculosis cases occurring during HIV care is possibly preventableSkeie, L / Skrede, T / Maeland, A et al. | 2010
- P195
-
Generalized tuberculosis in HIV‐infected patients with AIDSZimina, VN / Vasilieva, IA / Kravchenko, AV / Batyrov, FA et al. | 2010
- P196
-
Therapy of the patients with HIV/TB infection and dynamics of level ‘naïve’ CD4‐lymphocytesPopova, AA / Kravchenko, AV / Kozhevnikova, GM / Serebrovskaya, LV et al. | 2010
- P197
-
Enfuvirtide in therapy at patients with HIV‐infection and tuberculosisKravchenko, AV / Kuznetsova, AV / Kozyrev, OA / Lukyanova, VA / Kanestri, VG et al. | 2010
- P198
-
Sudden unexplained death in a patient with HIV and MDR‐TBBoxall, E / Milne, J / Peters, E / Sykes, C et al. | 2010
- P199
-
Hepatitis C virus (HCV) infection and re‐infection among HCV‐ and HIV/HCV‐infected injection drug usersConway, B / Barrieshee, A / Tossonian, HK / Wight, K / Jassemi, S / Tong, M / Knight, E / Gallagher, L / Duncan, F / DeVlaming, S et al. | 2010
- P200
-
Increasing numbers of acute hepatitis C infections in HIV‐infected MSM and high reinfection rates following SVRStellbrink, HJ / Schewe, CK / Vogel, M / Noah, C et al. | 2010
- P201
-
High prevalence of genotype G in HIV co‐infected patients compared with HBV monoinfected patients in MéxicoMata‐Marín, JA / Gaytán‐Martínez, JE / Arroyo‐Anduiza, CI / Calderón‐Rodriguez, G et al. | 2010
- P202
-
Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the ‘real‐life setting’ proves the conceptIngiliz, P / Obermeier, MJ / Weitner, L / Cordes, C / Moll, A / Hintsche, B / Schlote, F / Köppe, S / Mayr, C / Baumgarten, A et al. | 2010
- P203
-
Correlates of hepatic stiffness by FibroScan© in a multicentric Italian cohort of HIV‐infected patientsTarquini, P / Sozio, F / Marchionni, E / Gabrielli, E / Polilli, E / Ancarani, F / Di Giammartino, D / Manzoli, LM / Parruti, G et al. | 2010
- P204
-
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV‐infected patientsFerrara, S / Tartaglia, A / Santantonio, T / Grisorio, B et al. | 2010
- P205
-
Do interleukin‐28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?Martín‐Carbonero, L / Rallón, NI / Benito, JM / Poveda, E / González‐Lahoz, J / Soriano, V et al. | 2010
- P206
-
No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCVFernández‐Montero, JV / Martín‐Carbonero, L / Barreiro, P / Rallón, NI / Benito, JM / González‐Lahoz, J / Soriano, V et al. | 2010
- P207
-
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment‐naïve coinfected patientsMata‐Marín, JA / Arroyo‐Anduiza, CI / Arias‐Flores, R / Gaytán‐Martínez, JE et al. | 2010
- P208
-
Sustained virological response in HIV/HCV co‐infected patients without rapid virological response (RVR) on peginterferon‐ribavirin therapyLabarga, P / Vispo, ME / Guardiola, JM / Miralles, C / Martín‐Carbonero, L / Portu, J / Barreiro, P / Miralles, P / Morello, J / Tellez, MJ et al. | 2010
- P209
-
Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV‐infection without HAARTTsarenko, SP / Kravchenko, AV / Kanestri, VG / Maximov, SL et al. | 2010
- P210
-
Efficacy and safety of TMC278 in treatment‐naïve, HIV‐1‐infected patients with HBV/HCV co‐infection enrolled in the phase III ECHO and THRIVE trialsNelson, M / Amaya, G / Clumeck, N / Arns Da Cunha, C / Jayaweera, D / Junod, P / Taisheng, L / Tebas, P / Stevens, M / Buelens, A et al. | 2010
- P211
-
Response to treatment of hepatitis C in HCV/HIV co‐infected patients is not influenced by either abacavir or tenofovir with weight‐based ribavirinBhatti, L / Shah, S / Khanlou, H et al. | 2010
- P212
-
Efficiency of HIV‐1 PR‐RT genotyping is not impacted by co‐infection with HCVDeloof, ACA / De Wolf, H / Verlinden, Y / Villacian, J / Pattery, T et al. | 2010
- P213
-
Relationship between dynamics of Epstein‐Barr virus and immune activation in HIV‐1 infected subjects in the HAART eraCattelan, AM / Zanchetta, M / Sasset, L / Petrara, R / Freguja, R / Gianesin, K / Cecchetto, MG / Cremona, F / De Rossi, A et al. | 2010
- P215
-
Detrimental clinical interaction between ritonavir‐boosted protease inhibitors and vinblastin in HIV‐infected patients with Hodgkin lymphomaCingolani, A / Torti, L / Pinnetti, C / de Gaetano Donati1, K / Murri, R / Tacconelli, E / Larocca, LM / Teofili, L et al. | 2010
- P216
-
Cancer chemotherapy: early experience with combined chemotherapy for HIV‐infected Kaposi's sarcoma patients at Lighthouse clinic, Lilongwe, MalawiMulinde, HF / Tweya, H / Chiwoko, J / Feldacker, C / Phiri, S / Nyirenda, M / Weigel, R / Mlundira, L et al. | 2010
- P217
-
Trends in human papillomavirus (HPV) infection among HIV‐positive women in the pre‐HAART and HAART era in a Nigerian clinicOnigbogi, MO / Ojo, OY et al. | 2010
- P218
-
Review of HIV testing at a district general hospital in an area of high HIV prevalence following the introduction of new national guidelinesPage, ID / Phillips, M / Flegg, P / Palmer, R et al. | 2010
- P219
-
HIV testing in non‐traditional settings: feasibility and acceptability in an acute admissions unitCridford, R / Thornton, A / Rayment, M / Mguni, S / Millett, D / Mandalia, S / Nardone, A / Tenant‐Flowers, M / Sullivan, A / Ghosh, R et al. | 2010
- P220
-
Clinical profile of HIV/AIDS patients admitted to a tertiary outpatient clinic in Istanbul, TurkeyAydin Altuntas, O / Kumbasar Karaosmanoglu, H / Korkusuz, R / Nazlican, O et al. | 2010
- P221
-
Aetiologies and factors associated with mortality among HIV‐infected patients at Taraba State Specialist Hospital, Jalingo, NigeriaDashe, DR et al. | 2010
- P222
-
Causes of death in patients infected with HIV from 1985 to 2008Mendez, J / Sarmento e Castro, R / Domingues da Silva, AR et al. | 2010
- P223
-
Syphilis infection is associated with an increase in plasma viral load in HIV infected patients: results from the FHDH cohort — ANRS CO4Jarzebowski, W / Piketty, C / de Truchis, P / Caumes, E / Farhi, D / Lascaux, AS / Bouldouyre, MA / Derradji, O / Pacanowski, J / Dupin, N et al. | 2010
- P224
-
Low immunogenicity of whole virion, verocell‐derived, inactivated, pandemic influenza H1N1 vaccine in HIV‐infected patientsLagler, H / Grabmeier‐Pfistershammer, K / Touzeau‐Römer, V / Tobudic, S / Rieger, A / Burgmann, H et al. | 2010
- P225
-
No effect of a single supratherapeutic dose of lersivirine, a next‐generation NNRTI, on QTc interval in healthy subjectsVourvahis, M / Wong, R / Ndongo, NM / O'Gorman, M / Tawadrous, M et al. | 2010
- P226
-
Leukocyte extract reduces HIV replication and modulates cellular factors involved in HIV infection: therapeutic meantFernandez‐Ortega, C / Casillas, D / Dubed, M / Navea, L / Ramirez, A / Lopez, L / Paneque, T / Reinoso, Y et al. | 2010
- P227
-
Therapeutics designed to neutralize soluble HIV tat protein could preserve IL‐7 signaling and CD8 T‐cell function in HIV+ patientsFaller, EM / Sugden, SM / MacPherson, PA et al. | 2010
- P228
-
Novel monitoring technique to minimise the risk for patients participating in pilot studies of investigational compoundsCuffe, R / Ait‐Khaled, M / Hughes, S / Min, S / Nichols, G / Thomas, D / Underwood, M / Yeo, JM et al. | 2010
- P230
-
Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV‐infected and uninfected subjectsGalli, L / Salpietro, S / Pellicciotta, G / Galliani, A / Piatti, PM / Hasson, H / Guffanti, M / Gianotti, N / Bigoloni, A / Lazzarin, A et al. | 2010
- P231
-
Smoking prevalence, cessation rates and relapse rates in the Swiss HIV Cohort Study (SHCS)Huber, M / Ledergerber, B / Jaccard, R / Elzi, L / Furrer, H / Hirschel, B / Cavassini, M / Bernasconi, E / Schmid, P / Weber, R et al. | 2010
- P232
-
Prevalence and risk factors for chronic obstructive lung disease in HIV‐infected patients in the HAART eraMadeddu, G / Fois, AG / Calia, GM / Becciu, F / Piras, B / Fiori, ML / Spada, V / Lovigu, C / Mannazzu, M / Pirina, P et al. | 2010
- P233
-
High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV‐infected subjectsSpagnuolo, V / Galli, L / Salpietro, S / Vinci, C / Cossarini, F / Travi, G / Rubinacci, A / Mignogna, G / Cernuschi, M / Bossolasco, S et al. | 2010
- P234
-
Cost‐effectiveness of atazanavir‐ritonavir versus lopinavir‐ritonavir in HIV patients initiating first‐line antiretroviral therapyBroder, MS / Juday, T / Uy, J / Chang, EY / Bentley, TGK et al. | 2010
- P235
-
Cost‐efficacy analysis of the MONET trial using Spanish antiretroviral drug pricesArribas, JR / Hill, A / Garcia, I / Anceau, A et al. | 2010
- P236
-
Late versus non‐late presentation of HIV/AIDS: an economic impact analysisGrabmeier‐Pfistershammer, K / Rieger, A / Schroeck, T / Schlag, M et al. | 2010
- P237
-
Cost‐effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimenAragão, F / Vaz Pinto, I / Vera, J et al. | 2010
- S1
-
An introduction to family‐centred services for children affected by HIV and AIDSRichter, Linda et al. | 2010
- S1
-
5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice ‐ IntroductionKort, Rodney et al. | 2010
- S2
-
5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice – Basic sciencesMascolinli, Mark / Kort, Rodney et al. | 2010
- S2
-
Family‐centred approaches to the prevention of mother to child transmission of HIVBetancourt, Theresa S / Abrams, Elaine J / McBain, Ryan / Fawzi, Mary C Smith et al. | 2010
- S3
-
5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice – Clinical sciencesMascolinli, Mark / Kort, Rodney et al. | 2010
- S3
-
Lessons learned from family‐centred models of treatment for children living with HIV: current approaches and future directionsLeeper, Sarah C / Montague, Brian T / Friedman, Jennifer F / Flanigan, Timothy P et al. | 2010
- S4
-
5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice – Biomedical preventionMascolinli, Mark / Kort, Rodney et al. | 2010
- S4
-
Fathers and HIV: considerations for familiesSherr, Lorraine et al. | 2010
- S5
-
5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice – Operations researchKort, Rodney et al. | 2010
- S5
-
Data availability on men's involvement in families in sub‐Saharan Africa to inform family‐centred programmes for children affected by HIV and AIDSHosegood, Victoria / Madhavan, Sangeetha et al. | 2010
- S6
-
Children of female sex workers and drug users: a review of vulnerability, resilience and family‐centred models of careBeard, Jennifer / Biemba, Godfrey / Brooks, Mohamad I / Costello, Jill / Ommerborn, Mark / Bresnahan, Megan / Flynn, David / Simon, Jonathon L et al. | 2010
- S7
-
The impact of HIV and high‐risk behaviours on the wives of married men who have sex with men and injection drug users: implications for HIV preventionSolomon, Sunil S / Mehta, Shruti H / Latimore, Amanda / Srikrishnan, Aylur K / Celentano, David D et al. | 2010
- S8
-
Family‐based HIV prevention and intervention services for youth living in poverty‐affected contexts: the CHAMP model of collaborative, evidence‐informed programme developmentBhana, Arvin / McKay, Mary M / Mellins, Claude / Petersen, Inge / Bell, Carl et al. | 2010
- S9
-
Family‐centred HIV interventions: lessons from the field of parental depressionTomlinson, Mark et al. | 2010